



Sumitomo Dainippon
Pharma

Innovation today, healthier tomorrows

Sumitomo Dainippon Pharma Co.,Ltd. Corporate Profile

Sumitomo Dainippon Pharma Co., Ltd., operates every day to achieve its corporate mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide”. By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission.

With our acquisition of Sepracor Inc. (current Sunovion Pharmaceuticals Inc.) in 2009, we have established our own sales and marketing infrastructure in the U.S. The globalization of our operations has progressed significantly by the 2011 launch of Latuda®, a key product in our global business strategy. We were also successful in gaining a strong foothold in the oncology area through the 2012 acquisition of Boston Biomedical Inc., a U.S. biotechnology venture company.

In our Third Mid-term Business Plan that began in 2013, our corporate vision is two-fold: “Aspire to be a globally active R&D-based company” and “Contribute to medical care through leading-edge technologies.” For the realization of this vision, we are redoubling efforts to promote innovations. In addition to the focused research and development areas of Psychiatry & Neurology and Oncology, we are channeling our R&D energies also into two new fields: diseases for which no approved drugs exist as well as Regenerative Medicine / Cell Therapy.

Constantly aware of our responsibility to you and all our stakeholders from patients, their families and medical caregivers to our shareholders, employees and the communities where we work, we pledge our unflagging efforts to earn and maintain your trust in us. On behalf of all us at Sumitomo Dainippon Pharma, I would like to ask for your continued support and encouragement.



Masayo Tada
Representative Director,
President and CEO

Corporate Mission

To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

Management Mission

- To contribute to healthcare and people's well-being based upon the principles of patient-oriented management and innovative research
- To continuously strive to maximize corporate value through constant business development and to fulfill shareholder expectations
- To create an environment in which employees can fulfill their potential and increase their creativity
- To maintain the trust of society and to contribute to the realization of a better global environment

Declaration of Conduct

At Sumitomo Dainippon Pharma, directors and employees alike are determined to pursue corporate activities following the Declaration of Conduct shown below, not to mention abiding by laws and regulations, so that we will win greater trust of society and become an innovative company.

1. Follow through the global slogan "Innovation today, healthier tomorrows."

We will constantly pursue self-innovation to deliver innovative products and services with speed so that people around the world can lead healthier and more fulfilling lives.

2. Pursue trustworthy corporate activities

We will comply with laws and regulations, and conduct transparent and fair corporate activities with a strong commitment to ethical behavior. Also, we will reject all contacts with organizations involved in illegal activities or which deviate from accepted standards of responsible social behavior.

3. Positively disclose information and properly manage information

We will ensure adequate, timely and fair information disclosure and properly protect and manage the personal and consumer information acquired in the course of our business activities.

4. Help employees reach their full potential

We will create a safe, encouraging work environment where employees are trusted to take the initiative and can demonstrate the full extent of their creativity.

5. Respect human rights

We will respect the rights of all people associated with our company in conducting corporate activities.

6. Positively address global environmental issues

We will take proactive, independent action on global environmental issues, recognizing this as a vital part of our corporate mission.

We will also offer environmentally friendly products and services.

7. Build harmonious relationships with society

As a good corporate citizen, we will engage in philanthropic activities and other activities of social benefit. We will also respect local cultures and customs both in and outside of Japan, and contribute to local community development through our corporate activities.



Brand Mark



“Green Prism”, the symbol of Sumitomo Dainippon Pharma Co., Ltd., is a motif in the design of the “Sun” — expressing a lively sense of energy, moving on toward tomorrow; “Light” — to convey the potential and hope of the future; and “Flower” — engendering the joyous and liberated sensation of basking in good health. A design crafted to embody preeminent research and development powers, a thorough support system, the spirit of challenge, and the other stances of Sumitomo Dainippon Pharma — a company bent on supplying all people with the strength to push on toward an even brighter tomorrow. Emanating from the symbol, furthermore, is the image of a network, steadily spreading out into the world. The corporate color of Green plays on the hue of fresh young leaves and other images of healthy and energetic moods, and signs of what the future holds.

Global Slogan

Innovation today, healthier tomorrows

Befitting Sumitomo Dainippon Pharma’s tenth anniversary of the merger, “Innovation today, healthier tomorrows” is the global slogan adopted by four pharmaceutical companies of Sumitomo Dainippon Pharma group (Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Boston Biomedical, and Sumitomo Pharmaceuticals (Suzhou)).

The global slogan reflects our full commitment to deliver to society revolutionary pharmaceuticals, acquired through groundbreaking ideas and high-standard research and development by each individual employee’s challenge for innovation, so as to help enable the patients and their families lead healthier and fulfilling lives.

Corporate Profile

Name	Sumitomo Dainippon Pharma Co., Ltd.
Established	May 14, 1897
Date of merger	October 1, 2005
Representative	Masayo Tada (President and Chief Executive Officer)
Capitalization	22.4 billion yen (as of December 31, 2016)
Employees	3,615 (6,490: consolidated) (as of December 31, 2016)
Business (consolidated)	Manufacturing and sales of Pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics and others
Osaka Head office	6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka, Japan (Zip code 541-0045) Main number: +81-6-6203-5321
Tokyo Head office	13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan (Zip code 104-8356) Main number: +81-3-5159-2500
Fiscal year	April 1 to March 31

In October 2005, Sumitomo Dainippon Pharma Co., Ltd. was formed through the merger of Dainippon Pharmaceutical Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma aims to actualize its vision of becoming “an innovative pharmaceutical company with a strong market presence.”

We are aiming for the enhancement of the domestic revenue base, promotion of the development of overseas business, enhancement of development pipelines and development as well as making aggressive investments for future growth.

October 1, 2005 Sumitomo Dainippon Pharma created.

2006	<ul style="list-style-type: none"> ● AmBisome® (therapeutic agent for systemic fungal infection) launched.
2007	<ul style="list-style-type: none"> ● REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched. ● The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd. ● The mid-term business plan (for the period from fiscal 2007 to fiscal 2009) started.
2008	<ul style="list-style-type: none"> ● LONASEN® (atypical antipsychotic) launched. ● AVAPRO® (therapeutic agent for hypertension) launched.
2009	<ul style="list-style-type: none"> ● TRERIEF® (therapeutic agent for Parkinson’s disease drug) launched. ● A holding company (Dainippon Sumitomo Pharma America Holdings, Inc.) established in the United States. ● Acquired Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.), Sepracor (Current Sunovion Pharmaceuticals Inc.) became a wholly-owned subsidiary of U.S. holding company.
2010	<ul style="list-style-type: none"> ● MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched. ● The 2nd mid-term business plan (for the period from fiscal 2010 to fiscal 2014) started. ● Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) and Dainippon Sumitomo Pharma America, Inc. merged in the United States. ● METGLUCO® (biguanide oral hypoglycemic) launched. ● The Human Growth Hormone business transferred. ● The Animal Health Products business split off and DS Pharma Animal Health Co., Ltd. established. ● The Food & Speciality Products business integrated into its subsidiary Gokyo Trading Co., Ltd. and corporate name changed to DSP Gokyo Food & Chemical Co., Ltd. ● Sepracor Inc. changed its company name to Sunovion Pharmaceuticals Inc.
2011	<ul style="list-style-type: none"> ● LATUDA® (atypical antipsychotic) launched in the United States by Sunovion Pharmaceuticals Inc. ● SUREPOST® (rapid-acting insulin secretagogue) launched.
2012	<ul style="list-style-type: none"> ● Acquired Boston Biomedical, Inc. ● ZETONNA® (therapeutic agent for allergic rhinitis) launched in the U.S. by Sunovion Pharmaceuticals Inc. ● Sunovion Pharmaceuticals Inc. acquired Elevation Pharmaceuticals Inc. (Current SRD) ● AIMIX® (therapeutic agent for hypertension) launched.
2013	<ul style="list-style-type: none"> ● A Subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte Ltd.) established in Singapore. ● The 3rd mid-term business plan (for the period from fiscal 2013 to fiscal 2017) started. ● Dainippon Sumitomo Pharma Europe Ltd. changed its company name to Sunovion Pharmaceuticals Europe Ltd. ● Joint venture company (Create Vaccine Company, Ltd.) established. ● An anti-cancer drugs sales subsidiary company (Boston Biomedical Pharma, Inc.) established in the U.S.

2014	<ul style="list-style-type: none"> ● Joint venture company (Sighregen K.K.) established. ● Kobe Regenerative & Cellular Medicine Center opened. ● APTIOM® (antiepileptic) launched in the U.S. by Sunovion Pharmaceuticals Inc. ● LATUDA® (atypical antipsychotic) launched in the U.K. by Sunovion Pharmaceuticals Europe Ltd. ● Announced reorganization of product sites (Integation of productive functions of Ibaraki Plant and Suzuka Plant, Closure of Ehime Plant)
2015	<ul style="list-style-type: none"> ● Started promotion for the indication “pruritus in chronic liver disease patients” of REMITCH® ● Trulicity® (GLP-1 receptor agonist) launched.
2016	<ul style="list-style-type: none"> ● Sunovion Pharmaceuticals Inc. acquired Cynapsus Therapeutics Inc., a Canadian company (current Sunovion CNSDevelopment Canada ULC) ● A Subsidiary for Promotion of Authorized Generics and others (DS Pharma Promo Co., Ltd.) established.
2017	<ul style="list-style-type: none"> ● Acquired Tolero Pharmaceuticals, Inc. ● Boston Biomedical Pharma, Inc. integrated into its subsidiary Boston Biomedical, Inc. and corporate name changed to Boston Biomedical, Inc.

Dainippon Pharmaceutical Co., Ltd.

Dainippon Pharmaceutical Co., Ltd., established on May 14, 1897. Twenty-one prominent leaders in the pharmaceutical industry in Doshomachi, Osaka, founded Osaka Pharmaceuticals Co., Ltd.

In 1898, Pharmaceutical Plant (former, Osaka Plant and former, Osaka Center) established in Ebie, Osaka. The company acquired the semigovernmental Dainippon Pharmaceutical Company in Tokyo and changed the name of the company to Dainippon Pharmaceutical Co., Ltd.

Sumitomo Pharmaceuticals Co., Ltd.

Sumitomo Pharmaceuticals Co., Ltd., established on February 6, 1984, from the Research, Development, and Manufacturing divisions of Sumitomo Chemical Co., Ltd.'s pharmaceuticals business, as well as the Pharmaceuticals Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company's pharmaceuticals.

The new company opened for business on October 1.

Corporate Governance

Basic concept on corporate governance

Sumitomo Dainippon Pharma Co., Ltd. (the “Company”) has established the Basic Policy on Corporate Governance and commits itself to continuously pursuing the establishment of a corporate governance system which is highly effective, aiming for the fuller realization of our Corporate Mission and Management Mission.

Factors that could significantly influence corporate governance

Sumitomo Chemical Co., Ltd. is the parent company of Sumitomo Dainippon Pharma with a 50.22% share of voting rights. Respect for autonomy is affirmed by the parent company and management independence is maintained, with no restraints on approvals or other matters by the parent company concerning Sumitomo Dainippon Pharma’s business operations. Furthermore, no directors of Sumitomo Chemical sit on the Sumitomo Dainippon Pharma Board of Directors. Sumitomo Dainippon Pharma retains some personnel seconded from the parent company based on Sumitomo Dainippon Pharma’s own judgment, and believes this has no influence on Sumitomo Dainippon Pharma’s management or business operations. Respect for autonomy is affirmed by the parent company and Sumitomo Dainippon Pharma’s independence is maintained. Based on the above, Sumitomo Dainippon Pharma believes that the interests of its retail shareholders are not impaired by its parent company.

Management structure

The Company has elected the organizational structure of a “Company with an Audit & Supervisory Board” and has appointed Independent Outside Directors to audit the execution of duties by the Directors, independent of the Board of Directors. In addition, the Company has adopted an executive officer system to separate management supervision from business execution.

The Board of Directors consists of eight members, including two Independent Outside Directors. The Board of Directors holds a meeting once a month, in principle, and resolves and reports on material business matters.

The Audit & Supervisory Board consists of five members, including three Outside Audit & Supervisory Board Members. The Audit & Supervisory Board holds a meeting once a month, in principle, discusses and resolves material matters relating to auditing, and also examines in advance to be submitted to the Board of Directors for discussion.

The Company has the Nomination and Compensation Committee, which holds a meeting as necessary, as a consultative body to the Board of Directors for enhancing the objectivity and independence of the functions of the Board of Directors on matters such as nomination of the candidates for Directors and Audit & Supervisory Board Members, and decisions on compensation of Directors. The Committee consists of three members, the majority of which being two Independent Outside Directors, and the chairperson be appointed from the Independent Outside Directors.

The Management Committee holds meetings twice a month, in principle, as a consultative body to the Representative Directors, President and CEO for the decision making for important business matters, based on the basic policy determined by the Board of Directors.

In addition, the Executive Committee holds a meeting once a month, in principle, for the purpose of appropriately sharing among the Directors and Audit & Supervisory Board Members, including the Outside Directors and the Outside Audit & Supervisory Board Members, the status of the execution of business and material matters relating to the execution of business.

Pharmaceuticals

The Sumitomo Dainippon Pharma Group sets the pharmaceuticals business, in order to deliver innovative and useful pharmaceuticals to people worldwide as well as in Japan we make every effort in applying advanced R&D to all of our new pharmaceuticals.

We advance the R&D for continuously creating new pharmaceuticals based on global development, and expand the pharmaceuticals business in Japan and worldwide.

Japan

Information provision activities

New drugs are delivered to patients after passing a long process that includes basic research, clinical studies and review by the government for regulatory approvals. Even after drug products are launched and used by a large number of patients, safety and efficacy are continually checked resulting in safe and secure, useful pharmaceuticals. It is only after proper usage has been established based on safety and efficacy information that the pharmaceuticals can fulfill their desired function of contributing effectively to human health requirements.

At Sumitomo Dainippon Pharma, we use our MR (Medical Representatives) to provide all of the requisite highly specialized information to personnel engaged in medical care. Our aim is to improve the confidence of medical personnel in Sumitomo Dainippon Pharma and to contribute via our daily MR activities to the betterment of healthcare and fuller lives of patients.

Focus marketing areas and key products

We have positioned Cardiovascular / Diabetes, Psychiatry & Neurology, and Speciality areas as our focus marketing areas and we are progressing sales activities in Japan.

In the Cardiovascular and Diabetes area, our hypertension therapeutic products include an angiotensin II receptor blocker (ARB), calcium channel blocker (CCB), combination product of ARB and CCB, diuretic, angiotensin-converting enzyme (ACE) inhibitors and an alpha-beta blocker thus enabling us to participate effectively in the treatment of hypertension. In the diabetes area, we also promote several products which have different mechanisms of action for type 2 diabetes in order to respond to a wide range of medical needs. In the Psychiatry & Neurology areas, we offer a number of therapeutic drugs covering a wide range of diseases from schizophrenia to Parkinson's disease, anxiety disorders and epilepsy. In addition, in our Speciality areas (areas with high unmet medical needs where high specialization is required), we respond to a wide range of medical needs through the promotion of a therapeutic agent for systemic fungal infection, an Anderson-Fabry disease drug and a therapeutic agent for hepatocellular carcinoma.

We aim to maximize earnings by concentrating sales resources on major pharmaceutical products.

Products lineup

Major pharmaceutical products	Therapeutic indication
TRERIEF®	Therapeutic agent for Parkinson's disease
LONASEN®	Atypical antipsychotic
REPLAGAL®	Anderson-Fabry disease drug
Trulicity®	GLP-1 receptor agonist
REMITCH®*	Therapeutic agent for pruritus
SUREPOST®	Rapid-acting insulin secretagogue
AIMIX®	Therapeutic agent for hypertension
AmBisome®	Therapeutic agent for systemic fungal infection
MIRIPLA®	Therapeutic agent for hepatocellular carcinoma
METGLUCO®	Biguanide oral hypoglycemic drug
AVAPRO®	Therapeutic agent for hypertension

* Marketed by Torii Pharmaceutical Co.,Ltd. Promoted for indication "pruritus in chronic liver disease patients" by Sumitomo Dainippon Pharma Co.,Ltd.

Aiming for the continuous creation of new drugs

At the Sumitomo Dainippon Pharma Group, we position the Psychiatry & Neurology and Oncology areas, both of which have high unmet medical needs, as our focus therapeutic areas where we are targeting the creation of innovative pharmaceuticals.

In the Psychiatry & Neurology areas, the Sumitomo Dainippon Pharma Group focuses on the improvement of current treatments that do not sufficiently result in adequate symptom relief, as well as the treatment of patients who do not respond enough to existing medicines, and promote research and development of therapeutic agents in schizophrenia, depression, Alzheimer's disease, and other disorders. In the Oncology area, under the global R&D system established by Boston Biomedical, Tolero Pharmaceuticals, and the DSP Cancer Institute, the Sumitomo Dainippon Pharma Group aims to lead the world in the cancer stem cell and hematologic malignancies, and continually create innovative products. In addition, the Sumitomo Dainippon Pharma Group will apply leading-edge science, such as iPS cells to drug discovery, while strengthening activities in regenerative medicines and cell therapy to develop therapeutics for refractory diseases.

At the initial stage of research, Sumitomo Dainippon Pharma is not only endeavoring to improve research efficiency by making use of advanced technologies it owns, such as genomics, proteomics, and metabolomics, as well as the K Supercomputer, that started functioning in September 2012, but also making efforts to apply state-of-the-art science, such as iPS cells, to drug discovery. Sumitomo Dainippon Pharma is currently promoting joint research with the Center for iPS Cell Research and Application (CiRA), Kyoto University, aiming to create new treatments for rare intractable diseases, and actively participating in a cooperative industry-government-academia project, Research on Intractable Diseases Making Use of Disease-Specific iPS Cells.

At the latter stage of research and at the development stage, Sumitomo Dainippon Pharma is optimizing the portfolio of the entire Sumitomo Dainippon Pharma Group from a global point of view, focusing on key therapeutic areas and including other areas as well. In addition, Sumitomo Dainippon Pharma is actively implementing product life cycle management, including the development of formulations that aims to maximize product values.

Full-scale participation in oncology

The Sumitomo Dainippon Pharma Group is enhancing its presence in Oncology with the aim of making it a future core business area in addition to Psychiatry & Neurology. In April 2012, Sumitomo Dainippon Pharma acquired U.S. biotechnology company Boston Biomedical, Inc., which specializes in the area of Oncology. With this acquisition, we made a full-scale start on our global expansion in Oncology.

With the aim to create innovative new drugs, in September 2012 we established the DSP Cancer Institute in Japan (Location: Osaka Research Center) as an organization independent from the Drug Research Division under the direct control of the president. In February 2013 we set up a new base in Cambridge, Massachusetts, U.S. in order to expand the scale of research activities of Boston Biomedical. In January 2017, we acquired Tolero Pharmaceuticals, Inc., which generates unique compounds expecting potential options for hematologic malignancies, and expand our global cancer research and development system.

Setting global development as a basic strategy

The Sumitomo Dainippon Pharma Group has R&D bases in the three regions of Japan, the U.S. and China that engage in collaborative activities under the management of the Chief Scientific Officer (CSO). The Sumitomo Dainippon Pharma Group established the Global Business Strategy Committee (GBSC) in April 2012 to make efficient the R & D management function of CSO. GBSC works to optimize the Sumitomo Dainippon Pharma Group's overall portfolio with a global perspective by discussing issues including global business strategy, licensing proposals, and strategic prioritization and resource allocation for R&D, in addition, discusses the promotion of projects in early development stages and other issues with a global perspective. As for clinical development, the Sumitomo Dainippon Pharma Group will strengthen the global seamless management and promote development in a speedier and more efficient manner under the Head of Global Clinical Development.

Pharmaceuticals production

Recognizing that pharmaceuticals play a vital role in maintaining human health, we are dedicated to assuring that all pharmaceutical products have their designed quality. Manufacturing and quality control of pharmaceuticals are required to be carried out strictly in accordance with Good Manufacturing Practice (GMP) standards in each country.

The pharmaceuticals manufactured by the Sumitomo Dainippon Pharma Group are exported around the world after obtaining approval from the regulatory authorities of importing nations, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Australia's Therapeutic Goods Administration (TGA). Therefore, operating standards in the Sumitomo Dainippon Pharma Group are consistent with the GMP standards of Europe and the United States. Furthermore, we have established a high level of facility design and a quality assurance system to meet strict quality standards at the global level, including audits by overseas partner companies and the guidelines of the International Conference on Harmonisation (ICH), which deliberates the harmonization of EU, U.S. and Japanese pharmaceutical regulations.

Global standards for quality assurance are expected to become increasingly rigorous. The Sumitomo Dainippon Pharma Group is therefore making proactive investments in manufacturing facilities — including a new solid dosage form facility and a restricted access barrier system (RABS) that increases the level of sterility assurance — to meet future standards. Our manufacturing, quality assurance and other related divisions will work in concert to continue to provide pharmaceuticals of the highest quality.

Manufacturing bases

■ Suzuka Plant

As a production site focusing on efficiency, Suzuka Plant maintains integrated pharmaceutical manufacturing facilities at which a full range of operations are conducted, from production of active pharmaceutical ingredients and finished products to packaging.

■ Ibaraki Plant

Since Technology Research and Development Division's Formulation Technology Research Department is located in the Ibaraki Plant, from manufacturing technology research to manufacturing and quality control practice, as an R&D-driven pharmaceuticals plant able to flexibly accommodate new products and technologies, this plant produces drugs in dosage forms, including solid dosages, powders, tablets, capsules and injections.

■ Ehime Plant

Ehime Plant manufactures sterile injectables under strict quality control system.

■ Oita Plant

Oita Plant is our core facility for active pharmaceutical ingredients. Operating 24 hours a day, 365 days a year, the plant manufactures active ingredients.

USA

Sunovion Pharmaceuticals Inc.

Sumitomo Dainippon Pharma acquired U.S. company, Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) in October 2009, and then merged it with our subsidiary Dainippon Sumitomo Pharma America Inc. in April 2010 and changed the company name to Sunovion Pharmaceuticals Inc. (Sunovion). Currently, Sunovion plays a major role in the North American business of the Sumitomo Dainippon Pharma Group.

Sunovion aims to maximize earnings from LATUDA® (launched in February 2011) in addition to optimizing the field force structure for existing products.

Corporate Profile

Sunovion is a pharmaceutical company that possesses all of the functions of such an enterprise including R&D, manufacturing and sale of ethical pharmaceuticals for the Psychiatry & Neurology and respiratory areas.

Established	January 1984
Head office location	Marlborough, Massachusetts, U.S.A.
Recent achievements	184.9 billion yen (FY 2015)

Product lineup

Major pharmaceutical products	Therapeutic indication
LATUDA®	Atypical antipsychotic
APTiom®	Antiepileptic
BROVANA®	Long-acting Beta-agonist
LUNESTA®	Sedative hypnotic
XOPENEX HFA®	Short-acting Beta-agonist
OMNARIS®	Corticosteroid nasal spray
ZETONNA®	Corticosteroid nasal spray
ALVESCO®	Inhaled corticosteroid

China

Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.

The Sumitomo Dainippon Pharma Group is positively deploying business in China by setting it as an important growing market. In this market, our subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. is in charge of operations, from the production to sale of four products locally including MEPem®. The plant at Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. currently packages our products for sale in the local market. Fully integrated production, from formulation to packaging, is currently being prepared. By bringing new products in addition to existing products to the market, we are aiming for steady growth.

Corporate Profile

Established	December 2003
Head office location	Suzhou Industrial Park, Jiangsu Province, People's Republic of China
Recent achievements	18.4 billion yen (FY 2015)

Product lineup

Major pharmaceutical products	Therapeutic indication
MEPEM [®] (Brand name in Japan: MEROPEN [®])	Carbapenem antibiotic
ALMARL [®] (Brand name in Japan: Arotinolol Hydrochloride)	Therapeutic agent for hypertension, angina pectoris and arrhythmia
SEDIEL [®]	Serotonin-agonist antianxiety drug
GASMOTIN [®]	Gastroprokine

Other Products

The food ingredients and chemical product materials business is handled by Sumitomo Dainippon Pharma subsidiary DSP Gokyo Food & Chemical Co., Ltd.

The animal health products business is conducted by Sumitomo Dainippon Pharma subsidiary DS Pharma Animal Health Co., Ltd.

Sumitomo Dainippon Pharma subsidiary DS Pharma Biomedical Co., Ltd. conducts the diagnostics and research materials business.

Board Members and Executive Officers

(as of April 1, 2017)

Post	Name
Representative Director, President and Chief Executive Officer	Masayo Tada
Representative Director, Executive Vice President Global Corporate Planning; External Affairs; Corporate Secretariat & Industry Affairs; Personnel; Finance & Accounting	Hiroshi Nomura
Member, Board of Directors, Senior Executive Officer Executive Director, Sales & Marketing Division	Hitoshi Odagiri
Member, Board of Directors, Executive Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Drug Research Division	Toru Kimura
Member, Board of Directors	Hiroshi Noguchi
Member, Board of Directors	Masaru Ishidahara
Member, Board of Directors (Outside)	Hidehiko Sato
Member, Board of Directors (Outside)	Hiroshi Sato
Audit & Supervisory Board Member	Nobuo Takeda
Audit & Supervisory Board Member	Yasuji Furutani
Audit & Supervisory Board Member (Outside)	Harumichi Uchida
Audit & Supervisory Board Member (Outside)	Yutaka Atomi
Audit & Supervisory Board Member (Outside)	Kazuto Nishikawa
Senior Executive Officer Chair and CEO, Sunovion Pharmaceuticals Inc.	Nobuhiko Tamura
Senior Executive Officer Executive Director, Manufacturing Division; Technology Research & Development Division	Yoshiharu Ikeda
Senior Executive Officer Boston Biomedical, Inc.; Global Oncology Office; Oncology Clinical Development Unit; Oncology Strategy Unit; Head of Global Oncology Office	Kazuo Koshiya
Executive Officer Executive Director, Corporate Regulatory Compliance & Quality Assurance Division; Regulatory Affairs; Medical Information; Medical Affairs; Drug Development Division	Nobuyuki Hara
Executive Officer Senior Director, Global Corporate Planning; Legal Affairs; Intellectual Property; IT Management & Digital Transformation	Hiroyuki Baba
Executive Officer Director, Corporate Governance; Corporate Service Center	Hajime Kinuta
Executive Officer Executive Director, Drug Research Division	Hideyuki Harada
Executive Officer Deputy Executive Director, Sales & Marketing Division	Mitsuyuki Taniguchi
Executive Officer Corporate Governance (External Communications); Personnel (Diversification)	Atsuko Higuchi


Board of Directors and Executive Officers

Executive Officer Senior Director, Global Business Development; International Business Management	Shigeyuki Nishinaka
---	---------------------

Executive Officer Executive Vice President, Chief Medical Officer, Sunovion Pharmaceuticals Inc.; Head of Global Clinical Development for Sumitomo Dainippon Pharma Group	Antony Loebel
--	---------------

Organizational Chart

(as of April 1, 2017)



Key Facilities

● Osaka Head Office

6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka, 541-0045, Japan
TEL : +81-6-6203-5321
FAX : +81-6-6202-6028

● Tokyo Head Office

13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-8356, Japan
TEL : +81-3-5159-2500
FAX : +81-3-5159-2945

● Tokyo Kyobashi Office

17-10, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-0031, Japan

● Regenerative & Cellular Medicine Kobe Center

Kobe KIMEC Center Building 5th Fl,
5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe,
Hyogo, 650-0047, Japan
TEL : +81-078-306-2170
FAX : +81-078-303-4040

● Suzuka Plant

1450 Yasuzuka-cho, Suzuka, Mie, 513-0818, Japan
TEL : +81-59-382-8951
FAX : +81-59-382-4505

● Ibaraki Plant

3-45, Kurakakiuchi 1-chome, Ibaraki, Osaka, 567-0878, Japan
TEL : +81-72-627-8112
FAX : +81-72-627-8110

● Ehime Plant

5-1, Sobiraki-cho, Niihama, Ehime, 792-0001, Japan
TEL : +81-897-37-7600
FAX : +81-897-35-2534

● Oita Plant

2200 Oaza Tsurusaki, Oita, Oita, 870-0106, Japan
TEL : +81-97-523-1177
FAX : +81-97-523-1121

■ Central Research Laboratories

33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan
TEL : +81-6-6337-5876
FAX : +81-6-6337-6538

■ Osaka Research Center

1-98, Kasugade-naka 3-chome, Konohana-ku, Osaka,
Osaka, 554-0022, Japan
TEL : +81-6-6466-5183
FAX : +81-6-6466-5483

● Tokyo Distribution Center

37-1, Kitatsuji, Kazo, Saitama, 347-0023, Japan
TEL : +81-480-65-2240
FAX : +81-480-65-2986

● Kobe Distribution Center

16-2, Yasakadai 3-chome, Suma-ku, Kobe, Hyogo, 654-0161, Japan
TEL : +81-78-796-0150
FAX : +81-78-796-0154

Overseas Local Subsidiaries

● Dainippon Sumitomo Pharma America Holdings, Inc.

84 Waterford Drive Marlborough, MA 01752
TEL : +1-508-481-6700
FAX : +1-508-481-7683

● Sunovion Pharmaceuticals Inc.

84 Waterford Drive Marlborough, MA 01752
TEL : +1-508-481-6700
FAX : +1-508-481-7683

● Boston Biomedical, Inc.

640 Memorial Drive, Cambridge, MA 02139
TEL : +1-617-674-6800
FAX : +1-617-674-8661

● Tolero Pharmaceuticals, Inc.

2975 West Executive Parkway Suite #320 Lehi, UT 84043
TEL : +1-801-285-6003
FAX : +1-801-746-3314

● Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.

No.115 QingQiu Street, SIP, Jiangsu Province, 215126 China
TEL : +86-512-6283-1082
FAX : +86-512-6283-1083

● Sunovion Pharmaceuticals Europe Ltd.

First Floor, Southside, 97-105 Victoria Street,
London SW1E 6QT, U.K.
TEL : +44- (0) 20-7821-2840
FAX : +44- (0) 20-7821-2841

● Sunovion Pharmaceuticals Asia Pacific Pte. Ltd.

150 Beach Road, #14-03 Gateway West, Singapore 189720



Sumitomo Dainippon
Pharma

Innovation today, healthier tomorrows